STRO sutrobio.com: Enterprise Value to EBITDA Ratio

Graphic logo of Sutro Biopharma (STRO)

Sutro Biopharma, Inc. (STRO) is developing targeted immunotherapy and antibody-drug conjugates, mitigating risks through partnerships to treat various tumors. High demand for innovative cancer treatments is driving the expansion of its agreement network, while the price trajectory of the securities on GURU.Markets based on the EV/EBITDA metric is fixed at 0.00. Sutro Biopharma, Inc. (STRO) monetizes its technological platform, securing stable funding through long-term contracts with global industry leaders.

Sutro Bio - STRO Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/11/2026)

Summary analytical data breakdowns for sutrobio.com (STRO)

- stock price and consensus target price:
Stock Quotes Sutro Bio|STRO - Average Forecast Price
- company stock capitalization data:
Market Valuation Sutro Biopharma, Inc|STRO - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Sutro Biopharma|STRO - Book Valuation of Business|Market Value to Book Value Ratio sutrobio.com|STRO - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Sutro Biopharma, Inc.|STRO - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Sutro Biopharma|STRO - Company Aggregate Debts|Debt to Book Capitalization Ratio Sutro Biopharma, Inc|STRO - Company Long-Term Indebtedness|Company Short-Term Debt Sutro Biopharma|Quick Liquidity Indicator sutrobio.com
- financial results and valuation multiples details:
STRO - Annual Net Income|Future Profit Sutro Biopharma, Inc.|STRO - Market Price to Net Income Ratio|Forward P/E Multiple Sutro Biopharma, Inc.|STRO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Sutro Biopharma, Inc|STRO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Sutro Biopharma|STRO - Earnings per share for the trailing year|Quarterly EPS earnings growth sutrobio.com|STRO - Earnings growth in current year|Net earnings per share growth forecast for next year Sutro Biopharma, Inc.
Fundamental company analysis:STRO (Sutro Bio)
Original product of Sutro Biopharma Inc.

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, allowing for an assessment of the actual payback period of assets regardless of debt load. By analyzing the dynamic EV/EBITDA metric of the company, an investor can evaluate the stability of Sutro Biopharma, Inc. (STRO), where the risk of narrow specialization in ovarian cancer therapy is offset by the inflow of capital from global strategic partners.

Competitor analysis for Sutro Biopharma, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|TSBX (turnstonebio.com) - Enterprise Value to EBITDA Ratio|Vaccinex Inc. (VCNX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio HARP